B2B Growth Marketing Lead, Flow Neuroscience
+ Share options
1 day a week in office (Battersea Power Station, London)
Wearable home treatment for depression
Open for applications
Wearable home treatment for depression
21-100 employees
Open for applications
+ Share options
1 day a week in office (Battersea Power Station, London)
21-100 employees
Company mission
To find new ways of treating mental health issues, using science and technology.
Jump to section
Company mission
To find new ways of treating mental health issues, using science and technology.
Few candidates hear
back within 2 weeks
Our take
Despite the prevalence of mental health conditions such as anxiety and depression, medicine has been relatively slow to respond with new treatment options. Particularly, at-home treatment has been limited to medication, or more recently virtual talk therapy. Flow Neuroscience has developed a wearable tDCS (transcranial Direct Current Stimulation) device for patients to use at home, with a complementary app to help manage the symptoms of major depressive disorder.
Flow’s treatment, the first of its kind approved for home use in Europe, allows users to administer tCDS without a doctor and away from a clinical setting. The company has been committed to following the rigorous medical research and testing framework, with the device undergoing early trials in the UK and EU, which have so far received positive results from users.
In 2022, Flow Neuroscience collaborated with Curebase to launch a large-scale FDA-approved clinical trial of its product. Off the back of this trial, the company entered the MedTech Innovator support programme in 2023. It will also seek FDA approval for its headset, which if successful will open the door for client reach expansion across the UK, EU, and US.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Remote & hybrid options
- Flexible working hours
- Be part of a small team scaling a cutting-edge product that could change the way the world thinks about mental health treatment
Funding (last 2 of 3 rounds)
Aug 2021
$8.9m
SERIES A
Jul 2019
$1.4m
EARLY VC
Total funding: $11.4m
This company has top investors
Leadership
Daniel Månsson
(Chief Clinical Officer)Former CEO of the company. Previously a Clinical Psychologist at Østfold Hospital Trust.
Erik M. Rehn
(CTO)Co-Founder and Board Member at Slagkryssaren. Co-Founder and former VP at Stockholm.AI.